Genenta Science provides update from TEM-GBM study

Genenta Science (GNTA) announced an update from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme patients with an unmethylated MGMT gene promoter. As of the November 21, data cut, 25 patients have been treated with Temferon. These data are compared to the previously disclosed April 15 cut, communicated on July 1. More than seven months after the prior update, key survival metrics for the TEM-GBM patients remain consistent. In total, 44% of patients have reached 18-month survival, compared to 38% reported in April. Two-year survival rate continues to be 29% and median overall survival remains at 17 months, both consistent with prior findings. For context, historical cohorts of uMGMT patients treated with standard of care typically show a two-year survival rate of approximately 14% and median overall survival of 13-15 months. The study includes the first patient who has reached three years of survival following Temferon administration. During this period, the patient did not receive additional therapeutic interventions or second-line treatments. At the follow-up visit conducted at three years, imaging indicated disease progression and the patient subsequently underwent a second surgery. The patient has continued on protocol-scheduled assessments and has recently completed the 3.5-year follow-up visit within the long-term surveillance study. This patient is also the second in the study who has not required further therapeutic interventions during the reported follow-up, a period that overlaps with the window in which recurrence is commonly observed in GBM. These observations are descriptive only, occur within a disease setting known for heterogeneous clinical courses, and individual patient outcomes may vary. As the first clinical setting in which the platform is being evaluated, the GBM study also provides early immune observations on Temferon’s behavior within the tumor microenvironment. These preliminary findings include indications that bone-marrow-derived myeloid cells can reach the tumor site and deliver immunotherapeutic payloads in situ, in a manner that is consistent with the intended design of the platform. While exploratory in nature and subject to further confirmation in larger controlled studies, these observations are helping to inform the broader development of Temferon – including potential combination approaches – and the evolution of the underlying cell-based delivery technology.